Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Price Crosses Below 50 Day Moving Average of $1.08

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRSGet Rating) shares crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.08 and traded as low as $0.93. Pieris Pharmaceuticals shares last traded at $0.94, with a volume of 4,307,414 shares.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Pieris Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, November 14th.

Pieris Pharmaceuticals Stock Performance

The firm has a market cap of $70.02 million, a P/E ratio of -2.00 and a beta of 1.08. The firm has a fifty day moving average of $1.08 and a 200-day moving average of $1.51.

Pieris Pharmaceuticals (NASDAQ:PIRSGet Rating) last announced its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. The business had revenue of $5.37 million for the quarter, compared to the consensus estimate of $4.51 million. Pieris Pharmaceuticals had a negative return on equity of 75.31% and a negative net margin of 121.78%. Equities research analysts expect that Pieris Pharmaceuticals, Inc. will post -0.63 earnings per share for the current year.

Institutional Trading of Pieris Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Tower Research Capital LLC TRC lifted its holdings in shares of Pieris Pharmaceuticals by 9,665.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 21,581 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 21,360 shares during the last quarter. Mackenzie Financial Corp bought a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter worth approximately $26,000. Oppenheimer & Co. Inc. bought a new stake in shares of Pieris Pharmaceuticals in the 1st quarter worth approximately $32,000. Mirabella Financial Services LLP bought a new stake in shares of Pieris Pharmaceuticals in the 1st quarter worth approximately $39,000. Finally, Two Sigma Investments LP bought a new stake in Pieris Pharmaceuticals during the 3rd quarter valued at $43,000. Institutional investors own 50.17% of the company’s stock.

Pieris Pharmaceuticals Company Profile

(Get Rating)

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids.

Featured Stories

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.